Iovance Biotherapeutics Inc. [NASDAQ: IOVA] gained 4.99% or 1.09 points to close at $22.92 with a heavy trading volume of 2388989 shares. The company report on July 20, 2021 that Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 5, 2021.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter financial results on Thursday, August 5, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.
To participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 1489438. The live webcast can be accessed in the Investors section of the Company’s website at www.iovance.com. The archived webcast will also be available for one year in the Investors section at www.iovance.com.
It opened the trading session at $21.92, the shares rose to $23.34 and dropped to $21.92, the range by which the price of stock traded the whole day. The daily chart for IOVA points out that the company has recorded -46.17% loss over the past six months. However, it is still -44.33% lower than its most recent low trading price.
If we look at the average trading volume of 3.71M shares, IOVA reached to a volume of 2388989 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Iovance Biotherapeutics Inc. [IOVA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IOVA shares is $40.31 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IOVA stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JMP Securities have made an estimate for Iovance Biotherapeutics Inc. shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on June 10, 2021. While these analysts kept the previous recommendation, Piper Sandler dropped their target price from $35 to $18. The new note on the price target was released on May 20, 2021, representing the official price target for Iovance Biotherapeutics Inc. stock.
The Average True Range (ATR) for Iovance Biotherapeutics Inc. is set at 1.32 The Price to Book ratio for the last quarter was 5.22, with the Price to Cash per share for the same quarter was set at 3.85.
Trading performance analysis for IOVA stock
Iovance Biotherapeutics Inc. [IOVA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.37. With this latest performance, IOVA shares dropped by -14.89% in over the last four-week period, additionally sinking by -46.17% over the last 6 months – not to mention a drop of -20.42% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IOVA stock in for the last two-week period is set at 44.86, with the RSI for the last a single of trading hit 44.11, and the three-weeks RSI is set at 45.36 for Iovance Biotherapeutics Inc. [IOVA]. The present Moving Average for the last 50 days of trading for this stock 22.74, while it was recorded at 22.67 for the last single week of trading, and 34.76 for the last 200 days.
Iovance Biotherapeutics Inc. [IOVA]: A deeper dive into fundamental analysis
Iovance Biotherapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.00 and a Current Ratio set at 11.00.
An analysis of insider ownership at Iovance Biotherapeutics Inc. [IOVA]
There are presently around $3,648 million, in the hands of institutional investors. The top three institutional holders of IOVA stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 19,726,650, which is approximately 28.951% of the company’s market cap and around 0.62% of the total institutional ownership; VANGUARD GROUP INC, holding 12,053,487 shares of the stock with an approximate value of $276.27 million in IOVA stocks shares; and FRANKLIN RESOURCES INC, currently with $206.53 million in IOVA stock with ownership of nearly 0.919% of the company’s market capitalization.
143 institutional holders increased their position in Iovance Biotherapeutics Inc. [NASDAQ:IOVA] by around 24,810,299 shares. Additionally, 129 investors decreased positions by around 14,635,868 shares, while 34 investors held positions by with 119,735,060 shares. The mentioned changes placed institutional holdings at 159,181,227 shares, according to the latest SEC report filing. IOVA stock had 39 new institutional investments in for a total of 1,275,326 shares, while 57 institutional investors sold positions of 2,773,558 shares during the same period.